View interactive charts of activity data from GtoPdb and ChEMBL (where available) across species
|Preclinical studies of baricitinib have shown it to be effective in rat models of rheumatoid arthritis .
A single patient with alopecia areata (AA) with comorbid CANDLE syndrome (a immunoproteasome-related disorder with a prominent interferon (IFN) signature, a disease feature shared with AA), recruited to a clinical trial testing baricitinib as a treatment for their CANDLE syndrome (NCT01724580) experienced significant hair regrowth . Mechanistic assessment in a mouse AA model, confirmed that clinical improvement correlated with baricitinib-induced resolution of the IFN signature. Other JAK inhibitors such as tofacitinib and ruxolitinib have also been reported to promote hair regrowth in AA in early stage trials [2,6-7].